Gilead Sciences (GILD, Financial) has entered into an exclusive option and license agreement with Tubulis to discover and develop antibody-drug conjugates (ADCs) targeting solid tumors. Gilead will utilize Tubulis's proprietary platforms, Tubutecan and Alco5, to select optimal technology solutions. Tubulis will lead the discovery and development of ADC candidates based on topoisomerase I inhibitors, aiming to address challenges like insufficient efficacy and off-target toxicity.
In March, Tubulis raised $140 million in a B2 funding round to support the clinical development of next-generation ADCs, including TUB-040 and TUB-030. These candidates target tumor antigens Napi2b and 5T4, respectively. Tubulis will receive an upfront payment of $20 million and up to $415 million in potential milestone payments from Gilead.
